



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: February 08, 2018

To The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Security Code: 540596	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051 Symbol: ERIS
---	--

SUBJECT: INTIMATION OF SCHEDULE OF ANALYST & INVESTOR CALL PURSUANT TO REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)

Dear Sir/Madam,

This is further to our letter dated February 03, 2018 intimating about the date of the Board of Directors Meeting to inter alia, consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended December 31, 2017.

We wish to inform that pursuant to regulation 30 and other applicable regulations, if any, of the SEBI LODR, 2015 the Company proposes to hold a conference call for analysts and investors on Tuesday, February 13, 2018. The details of the said call is attached herewith and also available on Company's website.

Thanking you.

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary and Compliance Officer
Membership No.: A26493

Encl.:a/a

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



Axis House, C-2, Wadia International Centre, P.B Marg. Worli, Mumbai 400 025 (India)



Eris Lifesciences Ltd.

Q3FY18 Earnings Call on 13th February 2018
hosted by Axis Capital Limited

We are pleased to host, on behalf of Eris Lifesciences Ltd., a **conference call for analysts and investors on Tuesday, 13th February 2018** following the announcement of financial results for the quarter ended December 2017.

The call will be initiated with a brief management discussion on the earnings performance followed by an interactive Question & Answer session. The management team will be represented by

- ❑ **Amit Bakshi**, Chairman and Managing Director
- ❑ **Himanshu Shah**, Executive Director
- ❑ **Sachin Shah**, Chief Financial Officer

Details of the conference call are:

Date	:	Tuesday, 13th February 2018
Time	:	2:30 PM IST 05:00 PM HK/SG 9:00 AM UK
Call Leader	:	Mr. Prakash Agarwal, Axis Capital Limited

Country	Dial in numbers
Primary number	+91 22 3938 1075
India Local	+91 7045671221 (Available all over India)
International Dial In	
- Hong Kong	800 964 448
- Singapore	800 101 2045
- U K	0 808 101 1573
- USA	1 866 746 2133



Or Copy this URL in your browser: <http://services.choruscall.in/diamondpass/registration?confirmationNumber=3272289>

For further information please contact

Prakash Agarwal
Executive Director – Pharmaceuticals
Axis Capital Limited
Direct: +91 22 4325 1147
Mobile: +91 9820534334
Email: prakash.agarwal@axiscap.in

Gaurav Tinani
AVP – Pharmaceuticals
Axis Capital Limited
Direct: +91 22 4325 1132
Mobile: +91 8369382998
Email: gaurav.tinani@axiscap.in